Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. | Ramautarsing and Ananworanich AIDS Research and Therapy 2010 7 18 http content 7 1 18 AIDS RESEARCH AND THERAPY REVIEW Open Access Generic and low dose antiretroviral therapy in adults and children implication for scaling up treatment in resource limited settings Reshmie Ramautarsing 1 2 and Jintanat Ananworanich 1 3 4 Abstract Although access to antiretroviral therapy ART for the treatment of HIV has increased during the last decade many patients are still in need of treatment. With limited funds to provide ART to millions of patients worldwide there is a need for alternative ways to scale up ART in resource limited settings. This review provides an overview of pharmacokinetic safety and efficacy studies of generic and reduced dose ART. The production of generic ART has greatly influenced the decline in drug prices and the increased in ART access. Generic ART has good pharmacokinetic profile safety and efficacy. Toxicity is however the main cause for ART discontinuation. Several dose reduction studies have shown adequate pharmacokinetic parameters and short term efficacy with reduced dose ART. Ethnicity may affect drug metabolism several pharmacokinetic studies have confirmed higher plasma ART concentration in Asians. Randomized efficacy trial of reduced versus standard ART is warranted. Introduction In 2008 an estimated million adults and children were living with HIV worldwide 1 most of whom were from low and middle income countries and million people were in need of antiretroviral treatment ART 2 . However million people 58 had no access to treatment. Even though the great majority of HIV infected people live in Sub-Saharan Africa million HIV infected people are living in Asia 1 . The ART coverage in East South and South-East Asia was only 37 in 2008 3 . Although this is an increase compared to the 29 in 2007 the scaling up of antiretroviral therapy is still slow. This review will focus on two important ways of achieving
